Hipogonadismo masculino
- Gilberto Pérez López 1
- Susana Bacete Cebrián 1
- Laura González Fernández 1
- Olga González Albarrán 1
- 1 Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, España
ISSN: 0304-5412
Año de publicación: 2024
Título del ejemplar: Enfermedades endocrinológicas y metabólicas (V): Enfermedades hipotalámicas e hipofisarias (II)
Serie: 14
Número: 17
Páginas: 1004-1012
Tipo: Artículo
Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado
Resumen
Male hypogonadism (HG) is defined as the functional incompetence of the gonads with suboptimal or altered production of hormones and germ cells. The prevalence between 30 and 70 years of age is 10% and increases with age. It is classified according to the origin, as primary hypergonadotropic HG, secondary hypothalamic-pituitary hypogonadotropic HG and HG due to peripheral resistance to the androgenic effect. The diagnosis requires clinical suspicion and hormonal determinations that confirm it. The main treatment is the administration of testosterone by transdermal or injectable route, with the option of using GnRH or gonadotropins.
Referencias bibliográficas
- 1. Dean, J.D., et al. The International Society for sexual medicine's process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med. (2015)
- 2. Araujo, A.B., et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. (2007)
- 3. Bhasin, S., et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. (2018)
- 4. Dandona, P., et al. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. (2011)
- 5. Dohle, G.R., et al. EAU guidelines on male hypogonadism. Eur Assoc Urol. (2016)
- 6. Gianatti, E.J., et al. Testosterone deficiency in men with Type 2 diabetes: Pathophysiology and treatment. Diabet Med. (2020)